- Report
- January 2024
- 306 Pages
Global
€4594EUR$4,995USD£3,886GBP
- Report
- February 2022
- 112 Pages
Global
From €3219EUR$3,500USD£2,723GBP
- Drug Pipelines
- October 2020
- 2657 Pages
Global
From €2299EUR$2,500USD£1,945GBP
- Report
- May 2022
- 41 Pages
Global
From €2299EUR$2,500USD£1,945GBP
- Report
- May 2022
- 43 Pages
Global
From €2299EUR$2,500USD£1,945GBP
- Report
- May 2022
- 58 Pages
Global
From €2299EUR$2,500USD£1,945GBP
- Report
- May 2022
- 49 Pages
Global
From €2299EUR$2,500USD£1,945GBP
- Report
- May 2022
- 35 Pages
Global
From €2299EUR$2,500USD£1,945GBP
- Drug Pipelines
- December 2019
- 76 Pages
Global
From €3219EUR$3,500USD£2,723GBP
- Drug Pipelines
- December 2019
- 74 Pages
Global
From €3219EUR$3,500USD£2,723GBP
- Report
- August 2023
- 51 Pages
India
From €552EUR$600USD£467GBP
- Report
- August 2023
- 1350 Pages
Global
From €8185EUR$8,900USD£6,924GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4507EUR$4,900USD£3,812GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4507EUR$4,900USD£3,812GBP
- Report
- August 2023
- 300 Pages
Europe
From €4507EUR$4,900USD£3,812GBP
- Report
- August 2023
- 300 Pages
Middle East, Africa
From €4507EUR$4,900USD£3,812GBP
- Report
- August 2023
- 51 Pages
Argentina
From €552EUR$600USD£467GBP
- Report
- August 2023
- 51 Pages
South Korea
From €552EUR$600USD£467GBP
From €552EUR$600USD£467GBP
- Report
- August 2023
- 51 Pages
South Africa
From €552EUR$600USD£467GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more